Combination of | |
---|---|
Vildagliptin | Dipeptidyl peptidase-4 inhibitor |
Metformin | Biguanide antihyperglycemic agent |
Clinical data | |
Trade names | Eucreas, Galvumet, Zomarist, others |
AHFS/ Drugs.com | UK Drug Information |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Vildagliptin/metformin, sold under the brand name Eucreas among others, is a fixed-dose combination anti-diabetic medication for the treatment of type 2 diabetes. [3] It was approved for use in the European Union in November 2007, [4] and the approval was updated in 2008. [5] [6] [7] It combines 50 mg vildagliptin with either 500, 850, or 1000 mg metformin. [8]
The most common side effects include nausea (feeling sick), vomiting, diarrhea, abdominal (tummy) pain and loss of appetite. [4] [6] [7]
Vildagliptin/metformin is indicated in the treatment of type-2 diabetes mellitus: [4] [6] [7]